{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin+Lymphoma&page=20", "query": { "condition": "Non-Hodgkin Lymphoma", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 3563, "total_pages": 357, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin+Lymphoma&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Hodgkin+Lymphoma&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T04:22:13.997Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01090414", "title": "An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Idelalisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2010-03-22", "completion_date": "2018-06-18", "has_results": true, "last_update_posted_date": "2019-08-28", "last_synced_at": "2026-10-15T04:22:13.997Z", "location_count": 18, "location_summary": "Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 12 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01090414" }, { "nct_id": "NCT04644315", "title": "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms", "Colorectal Neoplasms", "Melanoma", "Pancreatic Neoplasms", "Sarcoma", "Ovarian Neoplasms", "Brain Neoplasms", "Thyroid Neoplasms", "Neuroendocrine Tumors", "Cholangiocarcinoma", "Salivary Gland Neoplasms", "Head and Neck Neoplasms", "Thyroid Cancer, Papillary", "Lymphoma, Large-Cell, Anaplastic", "Neoplasms by Site", "Respiratory Tract Neoplasms", "Thoracic Neoplasms", "Respiratory Tract Diseases", "Carcinoma, Bronchogenic", "Bronchial Neoplasms", "Intestinal Neoplasms", "Gastrointestinal Neoplasms", "Digestive System Neoplasms", "Digestive System Diseases", "Gastrointestinal Diseases", "Colonic Diseases", "Intestinal Diseases", "Central Nervous System" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-05-24", "completion_date": "2022-05-16", "has_results": true, "last_update_posted_date": "2023-08-07", "last_synced_at": "2026-10-15T04:22:13.997Z", "location_count": 29, "location_summary": "Culver City, California • Los Angeles, California • Sacramento, California + 21 more", "locations": [ { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Culver City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04644315" }, { "nct_id": "NCT02746952", "title": "Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "UCART19", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "16 Years to 69 Years" }, "enrollment_count": 25, "start_date": "2016-08-01", "completion_date": "2020-07-28", "has_results": false, "last_update_posted_date": "2021-10-01", "last_synced_at": "2026-10-15T04:22:13.997Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02746952" }, { "nct_id": "NCT00057447", "title": "Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Interferon Gamma-1b", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "InterMune", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 24, "start_date": "2003-03", "completion_date": "2004-06", "has_results": false, "last_update_posted_date": "2007-11-01", "last_synced_at": "2026-10-15T04:22:13.997Z", "location_count": 1, "location_summary": "Brisbane, California", "locations": [ { "city": "Brisbane", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00057447" }, { "nct_id": "NCT02061449", "title": "Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous T-cell Lymphoma" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Focal lesional radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2014-03", "completion_date": "2018-11-05", "has_results": false, "last_update_posted_date": "2018-12-24", "last_synced_at": "2026-10-15T04:22:13.997Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02061449" }, { "nct_id": "NCT00147485", "title": "A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "AG-024322", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2004-12", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2008-08-18", "last_synced_at": "2026-10-15T04:22:13.997Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Philadelphia, Pennsylvania", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00147485" }, { "nct_id": "NCT00901225", "title": "Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Non-Hodgkins Lymphoma", "Hodgkins Disease" ], "interventions": [ { "name": "G-CSF plus Plerixafor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 21, "start_date": "2009-05", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2014-05-07", "last_synced_at": "2026-10-15T04:22:13.997Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00901225" }, { "nct_id": "NCT01278615", "title": "Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Adult Diffuse Large Cell Lymphoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2010-12", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2016-02-03", "last_synced_at": "2026-10-15T04:22:13.997Z", "location_count": 16, "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 12 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01278615" }, { "nct_id": "NCT01484015", "title": "Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Lymphoblastic Leukemia", "Adult Acute Myeloid Leukemia", "Adult Burkitt Lymphoma", "Adult Diffuse Large Cell Lymphoma", "Adult Diffuse Mixed Cell Lymphoma", "Adult Diffuse Small Cleaved Cell Lymphoma", "Adult Hodgkin Lymphoma", "Adult Immunoblastic Large Cell Lymphoma", "Adult Lymphoblastic Lymphoma", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Breast Cancer", "Chronic Eosinophilic Leukemia", "Chronic Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Cutaneous T-cell Non-Hodgkin Lymphoma", "Disseminated Neuroblastoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Grade 1 Follicular Lymphoma", "Grade 2 Follicular Lymphoma", "Grade 3 Follicular Lymphoma", "Malignant Testicular Germ Cell Tumor", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Multiple Myeloma", "Mycosis Fungoides/Sezary Syndrome", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Neutropenia", "Nodal Marginal Zone B-cell Lymphoma", "Ovarian Epithelial Cancer", "Ovarian Germ Cell Tumor", "Plasma Cell Neoplasm", "Poor Prognosis Metastatic Gestational Trophoblastic Tumor", "Primary Myelofibrosis", "Prolymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Splenic Marginal Zone Lymphoma" ], "interventions": [ { "name": "cefepime hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2011-02", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2018-07-18", "last_synced_at": "2026-10-15T04:22:13.997Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01484015" }, { "nct_id": "NCT01897012", "title": "Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "MYC Positive", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Burkitt Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Recurrent Hodgkin Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Burkitt Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Follicular Lymphoma", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory Hodgkin Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Romidepsin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2013-07-17", "completion_date": "2018-11-30", "has_results": false, "last_update_posted_date": "2019-01-28", "last_synced_at": "2026-10-15T04:22:13.997Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01897012" } ] }